116 related articles for article (PubMed ID: 1623689)
21. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control.
Woll PJ; Ranson M; Margison J; Thomson Y; van der Water L; George N; Howell A
Ann Oncol; 1994 Sep; 5(7):597-600. PubMed ID: 7993834
[TBL] [Abstract][Full Text] [Related]
22. Use of adaptive control with feedback to individualize suramin dosing.
Scher HI; Jodrell DI; Iversen JM; Curley T; Tong W; Egorin MJ; Forrest A
Cancer Res; 1992 Jan; 52(1):64-70. PubMed ID: 1727387
[TBL] [Abstract][Full Text] [Related]
23. [Development of software for data analysis by therapeutic drug monitoring of teicoplanin, a glycopeptide antibiotic].
Niwa T; Tokuma Y; Ito T; Kimura J; Tabata K; Takagi A
Jpn J Antibiot; 2004 Aug; 57(4):413-9. PubMed ID: 15535042
[TBL] [Abstract][Full Text] [Related]
24. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
Small EJ; Halabi S; Ratain MJ; Rosner G; Stadler W; Palchak D; Marshall E; Rago R; Hars V; Wilding G; Petrylak D; Vogelzang NJ
J Clin Oncol; 2002 Aug; 20(16):3369-75. PubMed ID: 12177096
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.
Kelly WK; Curley T; Leibretz C; Dnistrian A; Schwartz M; Scher HI
J Clin Oncol; 1995 Sep; 13(9):2208-13. PubMed ID: 7545218
[TBL] [Abstract][Full Text] [Related]
26. Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Figg WD; Cooper MR; Thibault A; Headlee D; Humphrey J; Bergan RC; Reed E; Sartor O
Cancer; 1994 Sep; 74(5):1612-4. PubMed ID: 8062193
[TBL] [Abstract][Full Text] [Related]
27. Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate.
Hemady RK; Sinibaldi VJ; Eisenberger MA
Am J Ophthalmol; 1996 Mar; 121(3):291-6. PubMed ID: 8597272
[TBL] [Abstract][Full Text] [Related]
28. Suramin: is adaptive control necessary?
Kobayashi K; Vokes EE; Stefansson K; Janisch L; Vogelzang NJ; Berezin F; Ratain MJ
J Clin Oncol; 1992 Dec; 10(12):1984-5; author reply 1985-6. PubMed ID: 1453214
[No Abstract] [Full Text] [Related]
29. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients.
Delattre IK; Musuamba FT; Nyberg J; Taccone FS; Laterre PF; Verbeeck RK; Jacobs F; Wallemacq PE
Ther Drug Monit; 2010 Dec; 32(6):749-56. PubMed ID: 20962708
[TBL] [Abstract][Full Text] [Related]
30. Data modifications to phase I study of suramin.
Kobayashi K; Vokes EE; Vogelzang NJ; Ratain MJ
J Clin Oncol; 1996 Sep; 14(9):2623-4. PubMed ID: 8823343
[No Abstract] [Full Text] [Related]
31. A prospective study of suramin-induced peripheral neuropathy.
Chaudhry V; Eisenberger MA; Sinibaldi VJ; Sheikh K; Griffin JW; Cornblath DR
Brain; 1996 Dec; 119 ( Pt 6)():2039-52. PubMed ID: 9010008
[TBL] [Abstract][Full Text] [Related]
32. Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration.
Salinger DH; Vicini P; Blough DK; O'Donnell PV; Pawlikowski MA; McCune JS
J Clin Pharmacol; 2010 Nov; 50(11):1292-300. PubMed ID: 20075185
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
[TBL] [Abstract][Full Text] [Related]
34. Suramin-induced skin reactions.
O'Donnell BP; Dawson NA; Weiss RB; Myers CE; James WD
Arch Dermatol; 1992 Jan; 128(1):75-9. PubMed ID: 1531404
[TBL] [Abstract][Full Text] [Related]
35. Adaptive control methods for the dose individualisation of anticancer agents.
Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
[TBL] [Abstract][Full Text] [Related]
36. A sequential Bayesian algorithm for dose individualisation of carboplatin.
Duffull SB; Begg EJ; Robinson BA; Deely JJ
Cancer Chemother Pharmacol; 1997; 39(4):317-26. PubMed ID: 9025772
[TBL] [Abstract][Full Text] [Related]
37. [Cutaneous drug reaction caused by suramin in 4 patients with metastatic prostate cancer].
Wichterich K; Tebbe B; Handke A; Dieckmann KP; Gollnick H
Hautarzt; 1994 Feb; 45(2):84-7. PubMed ID: 8150636
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic parameters of vancomycin in critically ill patients.
Llopis-Salvia P; Jiménez-Torres NV
J Clin Pharm Ther; 2006 Oct; 31(5):447-54. PubMed ID: 16958822
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.
Leroux S; Turner MA; Guellec CB; Hill H; van den Anker JN; Kearns GL; Jacqz-Aigrain E; Zhao W;
Clin Pharmacokinet; 2015 Dec; 54(12):1273-85. PubMed ID: 26063050
[TBL] [Abstract][Full Text] [Related]
40. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]